Madrigal Pharmaceuticals, Inc. (MDGL)

614.73 +12.52 (+2.08%) USD  |  NASDAQ  |  Dec 24, 10:39
More

Madrigal Pharmaceuticals SG&A Expense (TTM): 715.08M for Sept. 30, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for MDGL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Amgen, Inc. 6.976B
Alnylam Pharmaceuticals, Inc. 1.181B
Amicus Therapeutics, Inc. 353.07M
Insmed, Inc. 631.20M
Ionis Pharmaceuticals, Inc. 351.68M